BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DARE-NL - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DARE-NL
X-ORIGINAL-URL:https://www.dare-nl.nl
X-WR-CALDESC:Events for DARE-NL
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Amsterdam
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20260414T170000
DTEND;TZID=Europe/Amsterdam:20260414T190000
DTSTAMP:20260422T212254
CREATED:20260402T113153Z
LAST-MODIFIED:20260422T120221Z
UID:8876-1776186000-1776193200@www.dare-nl.nl
SUMMARY:Join4ATMP - Listening to Experiences: The Impact of Patient Involvement in ATMP Clinical Trial Design
DESCRIPTION:The Join4ATMP project has announced the launch of its 2026 webinar series\, aimed at exploring how patient involvement can transform the design of Advanced Therapy Medicinal Product (ATMP) clinical trials. The first session is titled “Listening to Experiences: The Impact of Patient Involvement in ATMP Clinical Trial Design”. Find more information on the series and to registere here.
URL:https://www.dare-nl.nl/event/join4atmp-webinar-listening-to-experiences-the-impact-of-patient-involvement-in-atmp-clinical-trial-design/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Amsterdam:20260302T092500
DTEND;TZID=Europe/Amsterdam:20260302T123000
DTSTAMP:20260422T212254
CREATED:20260421T135332Z
LAST-MODIFIED:20260422T120221Z
UID:9144-1772443500-1772454600@www.dare-nl.nl
SUMMARY:EMA - Platform approaches in the non-clinical and clinical domains
DESCRIPTION:The European Medicines Agency organises a webinar bringing together regulators and medicine developers to discuss the use of platform approaches beyond the quality and manufacturing domains. \nThe proposal for the EU pharmaceutical legislation introduces the concepts of platform technologies and platform marketing authorisation. \nThe main objectives of the webinar are: \n\nClarifying the current EU legal framework for the development and marketing of individualised therapies (n=1) and for the use of prior knowledge in Marketing Authorisation dossiers;\nPresenting case studies on the use of platform approaches in the non-clinical and clinical domains and exploring their possible applications and values;\nDiscussing the challenges and identify opportunities related to the use of platform approaches;\nFacilitating the implementation of the EU pharmaceutical legislation provisions on platform technologies and platform marketing authorisation.\n\nYou can find the broadcast here. \n 
URL:https://www.dare-nl.nl/event/ema-platform-approaches-in-the-non-clinical-and-clinical-domains/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251204
DTEND;VALUE=DATE:20251205
DTSTAMP:20260422T212254
CREATED:20260422T063848Z
LAST-MODIFIED:20260422T120221Z
UID:9196-1764806400-1764892799@www.dare-nl.nl
SUMMARY:Johnson&Johnson - Reducing vein-to-vein time for cell therapy
DESCRIPTION:This event invites innovators to present solutions which can compress the vein-to-vein timeline and unlock the full potential of CAR-T therapy for more patients\, faster. One of the speakers also showcases their innovation in in vivo gene therapy as a next generation solution. You can press here to watch the webinar.
URL:https://www.dare-nl.nl/event/johnsonjohnson-reducing-vein-to-vein-time-for-cell-therapy/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251030
DTEND;VALUE=DATE:20251031
DTSTAMP:20260422T212254
CREATED:20260422T064724Z
LAST-MODIFIED:20260422T120221Z
UID:9203-1761782400-1761868799@www.dare-nl.nl
SUMMARY:EMA - Regulation of ATMPs in Europe: present and future
DESCRIPTION:In this webinar Dr. Ana Hidalgo-Simon will give an overview on the journey of ATMP development and what the future holds. You can view the webinar here.
URL:https://www.dare-nl.nl/event/ema-regulation-of-atmps-in-europe-present-and-future/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251007
DTEND;VALUE=DATE:20251008
DTSTAMP:20260422T212254
CREATED:20260422T070031Z
LAST-MODIFIED:20260422T120221Z
UID:9210-1759795200-1759881599@www.dare-nl.nl
SUMMARY:Oncode Accelerator - Building Bridges: From Concept to Clinic with Innovative ATMP pipelines
DESCRIPTION:Cell-based advanced therapy medicinal products (ATMPs) such as CAR T\, CAR NK\, TIL and TCR T therapies represent an emerging form of cancer treatment wherein engineered immune cells form the basis of the therapy.​ However\, the complex techniques needed to generate ATMPs\, and the biological demands to make them effective for various cancer types\, present many challenges. \nLed by pioneers in the field of cell and gene therapy\, the Oncode Accelerator Cell and Gene Therapy Workstream combines topnotch scientific experience with a multidisciplinary academic infrastructure to build and optimize robust preclinical pipelines for ATMP development. \nWatch the recording here of this expert-led webinar\, which took place on October 7th\, 2025 and begin to tap into their extensive scientific expertise\, and learn how you can leverage Oncode Accelerator’s innovative infrastructure and plug-and-play production modules for the development of oncological cell and gene therapies.
URL:https://www.dare-nl.nl/event/oncode-accelerator-building-bridges-from-concept-to-clinic-with-innovative-atmp-pipelines/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250512
DTEND;VALUE=DATE:20250513
DTSTAMP:20260422T212254
CREATED:20260422T070601Z
LAST-MODIFIED:20260422T120221Z
UID:9218-1747008000-1747094399@www.dare-nl.nl
SUMMARY:JOIN4ATMP - Streamlining the ATMP Development Pathway in the EU (Join4ATMP CAR-T Used Case)
DESCRIPTION:Watch the webinar here. Use the password: *5w7gi?D \n 
URL:https://www.dare-nl.nl/event/join4atmp-streamlining-the-atmp-development-pathway-in-the-eu-join4atmp-car-t-used-case/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250410
DTEND;VALUE=DATE:20250411
DTSTAMP:20260422T212254
CREATED:20260422T070814Z
LAST-MODIFIED:20260422T120221Z
UID:9223-1744243200-1744329599@www.dare-nl.nl
SUMMARY:JOIN4ATMP - Rare Disease ATMPs
DESCRIPTION:Watch the webinar here. Use passcode: b4UGM=Xi
URL:https://www.dare-nl.nl/event/join4atmp-rare-disease-atmps/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250326
DTSTAMP:20260422T212254
CREATED:20260422T071905Z
LAST-MODIFIED:20260422T120221Z
UID:9232-1742860800-1742947199@www.dare-nl.nl
SUMMARY:FAST - Challenges in ATMP innovation: LibMeldy
DESCRIPTION:FAST’s webinar series on challenges in ATMP innovation \nAdvanced Therapy Medicinal Products (ATMPs) promise to transform patient care and revolutionize health care. However\, developers often face significant challenges in getting these innovative therapies to patients. Common questions include: \n\nHow can you meaningfully engage patients in your ATMP research?What does it take to effectively design and conduct clinical trials?How do you navigate the complex web of ATMP laws and regulations?\n\nIn this episode experts will talk about the LibMeldy case. Click here to watch this webinar.
URL:https://www.dare-nl.nl/event/fast-challenges-in-atmp-innovation-libmeldy/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250319
DTSTAMP:20260422T212254
CREATED:20260422T071446Z
LAST-MODIFIED:20260422T120435Z
UID:9226-1742256000-1742342399@www.dare-nl.nl
SUMMARY:FAST - Challenges in ATMP innovation: iSTOP-CP: intranasal Stem cells to Treat Perinatal brain injury and combat Cerebral Palsy
DESCRIPTION:FAST’s webinar series on challenges in ATMP innovation \nAdvanced Therapy Medicinal Products (ATMPs) promise to transform patient care and revolutionize health care. However\, developers often face significant challenges in getting these innovative therapies to patients. Common questions include: \n\nHow can you meaningfully engage patients in your ATMP research?What does it take to effectively design and conduct clinical trials?How do you navigate the complex web of ATMP laws and regulations?\n\nIn this episode Manon Benders and Cora Nijboer of the UMCU will talk about the iSTOP-CP case. Click here to watch this webinar.
URL:https://www.dare-nl.nl/event/fast-challenges-in-atmp-innovation-istop-cp-intranasal-stem-cells-to-treat-perinatal-brain-injury-and-combat-cerebral-palsy/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241216
DTEND;VALUE=DATE:20241217
DTSTAMP:20260422T212254
CREATED:20260422T072827Z
LAST-MODIFIED:20260422T120439Z
UID:9238-1734307200-1734393599@www.dare-nl.nl
SUMMARY:Johnson&Johnson - Advancing cell & gene therapy by optimizing lentiviral vector design and production
DESCRIPTION:To meet the demand for innovative treatments based on cell therapy\, it’s essential that Johnson&Johnson delivers solutions that are both faster and more cost-effective. Optimizing lentiviral vector (LVV) design and production is critical for advancing a subset of these therapies like CAR-T. \nThe primary challenge lies in developing scalable production systems that achieve high viral titers while ensuring the purity and stability of viral vectors to preserve safety and efficacy. Moreover\, compliance with stringent regulatory requirements is paramount. \nIn this symposium\, Johnson&Johnson addresses  key questions facing the biotech industry today: What are some of the main challenges in improving cutting-edge manufacturing techniques? How can Johnson&Johnsonboost LVV yield and enhance safety profiles? What insights can we gain from viral vector production applied in other areas like vaccines and gene therapy? Watch the webinar here.
URL:https://www.dare-nl.nl/event/johnsonjohnson-advancing-cell-gene-therapy-by-optimizing-lentiviral-vector-design-and-production/
LOCATION:Online
CATEGORIES:Webinar
END:VEVENT
END:VCALENDAR